Castle Biosciences reported second quarter 2026 revenue of $103.5 million, up from $86.2 million in the prior year period. Total test reports for core revenue drivers (DecisionDx-Melanoma and TissueCypher) increased 32% year-over-year. The company raised its full-year 2026 revenue guidance to $365-375 million from a previous range of $345-355 million and now expects positive Adjusted EBITDA for the third quarter, fourth quarter, and the full year. Castle Biosciences operates in the medical diagnostics industry, developing molecular tests to guide patient care decisions.